Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and ...

XI'AN CITY, SHAANXI PROVINCE, CHINA, January 21, 2026 /EINPresswire.com/ -- The global nootropics and wellness ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock surged 11.63% after the company announced plans to advance its experimental oral obesity drug VK2735 into late-stage trials in the third ...

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran ®, was the 53rd most commonly ...

Ubos Executive Director Chris Mukiza said the donation is part of efforts to strengthen administrative data systems ...

Feb 11 (Reuters) - Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year. Shares of the company rose nearly 10% to $31.28 ...

The San Francisco Department of Public Health is trying out new strategies to tackle the city's drug crisis after seeing a ...